Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 2/20 | 0.32 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.30 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.30 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6523014 | 0.78 | DGAT1 (0.32) | MAPT | |
| SCHEMBL6525636 | 0.78 | KMO (0.36) | — | |
| SCHEMBL3653195 | 0.73 | SMN1; SMN2 (0.47) | LMNAMAPT | |
| SCHEMBL1144987 | 0.72 | KDM4E (0.44) | KDM4ELMNAMAPT | |
| SCHEMBL19596571 | 0.70 | KMO (0.48) | — | |
| SCHEMBL3654325 | 0.70 | KMO (0.34) | — | |
| SCHEMBL3659260 | 0.69 | NOTUM (0.34) | — | |
| SCHEMBL28242027 | 0.69 | KMO (0.40) | LMNA | |
| SCHEMBL17666340 | 0.68 | SMN1; SMN2 (0.34) | MAOAMAOBACHEMAPT | |
| SCHEMBL27817379 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205590-B1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2014-06-04 | — | — | EP | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20130029975-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029975-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
| EP-2205590-A1 | CGRP ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009050232-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059954-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | MAOA 882/4885MAOB 777/4885ACHE 1525/4885 |
| US-20130029975-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | MAOA 882/4885MAOB 777/4885ACHE 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.